Intra‐arterial locoregional therapy in the management of hepatocellular carcinoma

Abstract

http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/11-1-reading-ramanathan.html a video presentation of this article

Transcutaneous Electrical Acustimulation Improves Gastrointestinal Disturbances Induced by Transcatheter Arterial Chemoembolization in Patients With Liver Cancers

“…(TACE) is a palliative treatment for patients without a curative treatment option for intermediate-stage HCC (Barcelona Clinic Liver Cancer stage B) (3,4). TACE is an endovascular technique that delivers the combination of an anticancer agent and the iodized oil to local lesions of the tumor (5). Adverse events associated with gastrointestinal (GI) symptoms include nausea, vomiting, abdominal bloating, loss of appetite, constipation, and other symptoms (6).…”

Correlating serum alpha-fetoprotein in hepatocellular carcinoma with response to Yttrium-90 transarterial radioembolization with glass microspheres (TheraSphere™)

“…5 Conventional transarterial chemoembolization is limited by side effects but this has been improved through the use of drug-eluting beads (DEB-TACE). 6 Main portal vein thrombosis is often seen as a contraindication to chemoembolization due to the increased risk of hepatic insufficiency, but some studies have shown a potential benefit. 7 Transarterial radioembolization (TARE) is a targeted therapeutic approach which facilitates direct delivery of yttrium-90 loaded microspheres to the tumor and may be the preferred treatment in the case of portal vein thrombosis.…”